In general, squamous patients with NSCLC bear a heavier tumor mutational burden with exception of targetable genomic mutations (e.g., EGFR, KRAS, or ROS1) than nonsquamous patients with NSCLC (Rizvi et al., 2015). The gene discussed is KRAS; the disease is neoplasm.